Tixagevimab-cilgavimab is a PrEP option for COVID-19 infection. Prior to October 2022, the European Union (EU) authorized it for use in immunocompromised individuals and those who have a history of a severe adverse reaction to vaccination. However, in vitro studies concluded that tixagevimab and cilgavimab and its parental antibodies have reduced neutralizing activity against the BA.1 subvariant of the B.1.1.259 variant and virtually no neutralizing activity against some other Omicron variants, including BA.4.6. Some regulatory agencies are recommending an increased dosage, while the UK government no longer supports distribution of tixagevimab-cilgavimab at all as of October 2022, citing a lack of data regarding dose and efficacy against Omicron.
Learn more about monoclonal antibody use for COVID-19.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Fast Five Quiz: COVID-19 Prevention - Medscape - Dec 16, 2022.